24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension
Hae-Young Lee, Cheol-Ho Kim, Jae-Kwan Song, Shung Chull Chae, Myung Ho Jeong, Dong-Soo Kim, Byung-Hee Oh
Korean J Intern Med. 2017;32(6):1025-1036. Published online 2017 Oct 17 DOI: https://doi.org/10.3904/kjim.2016.094
Citations to this article as recorded by 
Trough-to-peak ratios and elimination half-lives of antihypertensive drugs: implications for 24-hour blood pressure control in primary care
Mar Serrat-Costa, Gabriel Coll de Tuero, Ernest Vinyoles Bargalló, Enric Estévez Rovira, Jordi Rosinach Bonet, Carles Albaladejo Blanco, José Pablo Agudo Ugena, Marco Paz Bermejo, Joan Torras Borrell, Oriol Rebagliato Nadal, Joan Antoni Vallès-Callol, Wil
Atención Primaria.2026; 58(10): 103566. CrossRef
Efficacy of angiotensin receptor blockers for nocturnal blood pressure reduction: a systematic review and meta-analysis
Jing Liu, Wei Chen, Shihuan Shao, Yuanyuan Chen, Hongyi Wang, Yang Xi, Luyan Wang
Annals of Medicine.2024;[Epub] CrossRef
Real-world efficacy of fimasartan vs. other angiotensin receptor blockers in combination with calcium channel blockers: a nationwide cohort study
Huijin Lee, Chan Soon Park, Bongseong Kim, Tae-Min Rhee, Heesun Lee, Yong-Jin Kim, Kyungdo Han, Hyung-Kwan Kim
Clinical Hypertension.2024;[Epub] CrossRef
Blood Pressure–lowering Effect of Fimasartan Versus Comparators: A Cross-inference With a Systematic Review and Meta-analysis Through a Quality-management System
Hojin Oh, Kang-Yeon Kim, Duk-Woo Yoo, In Mo Yoon
Clinical Therapeutics.2023; 45(5): 437. CrossRef
A Randomized, Double-blind, Active-controlled, Two Parallel-Group, Optional Titration, Multicenter, Phase IIIb Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without a Diuretic Combination in Elderly Patien
Hae-Young Lee, Kwang-il Kim, Sang Hyun Ihm, Moo-Yong Rhee, Il Suk Sohn, Sungha Park, Eun-Seok Jeon, Jong-Min Song, Wook Bum Pyun, Ki-Chul Sung, Moo Hyun Kim, Sang-Hyun Kim, Seok-Yeon Kim, Shin-Jae Kim, Eung Ju Kim, Jinho Shin, Sung Yun Lee, Kook-Jin Chun,
Clinical Therapeutics.2021; 43(10): 1746. CrossRef
Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study
Gyu Chul Oh, Kwon Wook Joo, Myung-A Kim, Dong-Ju Choi, Yoon Jun Kim, Hae-Young Lee
Drug Design, Development and Therapy.2020; Volume 14: 1341. CrossRef
Fimasartan
Akshyaya Pradhan, Vikas Gupta, Rishi Sethi
Journal of Family Medicine and Primary Care.2019; 8(7): 2184. CrossRef
PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives
Fabio Angeli, Paolo Verdecchia, Monica Trapasso, Marina Pane, Sara Signorotti, Gianpaolo Reboldi
Expert Opinion on Drug Metabolism & Toxicology.2018; 14(5): 533. CrossRef